• Who we are
Multispecific yet truly natural antibodies

Taking next generation, multispecific antibody technologies into Alzheimer’s Disease and Antimicrobial Resistance

Taking next generation, multispecific antibody technologies into Alzheimer’s Disease and Antimicrobial Resistance

Who we are
Who we are

Long term pharma and biotech professionals with a track record of leading projects from research into the market

Our antibody development roots go deep

Our focus
Our focus

Multispecific yet natural

Alzheimer’s Disease and Antimicrobial Resistance

CD47 Dual targeting
Our pipeline

Fully human bi- and multi-specific antibodies for the treatment of Alzheimer’s Disease and Antimicrobial Resistant infections

Safe and selective blockade of CD47 on tumors

Looking into the future
Looking into the future

Beyond bispecific antibodies

Beyond bispecific antibodies

previous arrow
next arrow

Who we are

Our team at the discoveric bio group has a track record in drug development and commercialization from biotech and Big Pharma. Our expertise goes from discovery through pre-clinical and clinical development into commercial excellence.

We collaborate with a wide network of world class experts and CROs to develop and advance our pipeline in Alzheimer’s Disease and Antimicrobial Resistance.

Back